Background. Clomiphene citrate (CC) is a safe and widely available first-line ovulation induction drug in women with polycystic ovary syndrome (PCOS). Obesity may trigger the syndrome development in the presence of genetic predisposition or independent causal factor by inducing low insulin sensitivity.
INTRODUCTION
Polycystic ovary syndrome (PCOS) is one of the most common causes of anovulatory infertility affecting 4-7% of women. Obesity may trigger syndrome development in the presence of genetic predisposition or independent causal factor by inducing low insulin sensitivity (1, 2) .
Clomiphene citrate (CC) is a convenient, widely available and safe first-line ovulation induction drug in PCOS women (3) . At present, CC nonresponse is identified 3 to 6 months after the initiation of treatment (4) . If diagnosed earlier, a change of treatment and the use of more effective alternatives to correct anovulation could be initiated. The aim of this study was to test the hypothesis that anti-Mullerian hormone (AMH) can be used to achieve this goal.
AMH, also known as Müllerian inhibiting substance, is a member of the transforming growth factor β (TGF-β) family, which comprises 35 structurally-related peptides, such as bone morphogenetic proteins, activins and inhibins and growth differentiation factors. Many of them have a role in the reproductive function of both sexes. The AMH gene is located on chromosome 19 and encodes a diametric 140 kDA glycoprotein. AMH is synthesized as a pro-hormone that undergoes cleavage at the site of action to generate a biologically active C-terminal fragment. AMH acts on its own specific type II receptor, AMHR2, to signal through a bone morphogenetic proteins-like pathway, recruiting one of the type I receptors: ALK 2, 3 or 6. AMH receptor downstream signaling involves cytoplasmic effectors, called receptorrelated SMAD proteins (R-Smads 1, 5 and 8) and common SMAD4 protein.
Once AMH binds to AMHR2, type I receptor is recruited forming a receptor complex resulting in the activation of type I receptor and causing phosphorylation of R-Smard proteins. These proteins bind to SMAD4 protein and the formed complex is translocated into the nucleus where it binds directly to DNA to regulate gene expression or interact with other DNA-binding proteins. Bioactive AMH was first detected in granulosa cells in the 1980s. It was later proved that AMH is produced from 36 weeks of gestation in human granulosa cells and is expressed until menopause.
Direct measurements of AMH production by human granulosa cells and follicular fluid in 2007 confirmed that the highest concentrations are in the small antral follicles and decrease significantly or are undetectable in follicles ≥10 mm (5).
SUBJECTS AND METHODS
The aims of this study were to compare the serum AMH levels in obese women with PCOS vs. obese women with normal ovulatory cycles, and to further assess the role of AMH as a predictor of ovulation induction by clomiphene citrate. AMH levels were determined using a standardised ELISA kit assay.
A controlled prospective trial was conducted at the Iasi "Cuza Voda" Obstetrics and Gynecology Hospital and Iasi "Omini" Reproductive Fertility Center between June 2010 and September 2012.
Fifty-six infertile obese women with PCOS and BMI greater than 30kg/ m 2 (study group) and 30 women with normal ovulation (control group) were enrolled. All patients signed an informed consent.
The inclusion criteria for obese women with PCOS were those recommended by the 2003 Rotterdam Consensus Conference on the diagnosis and treatment of polycystic ovary syndromes. Only women with anovulatory infertility were enrolled. The obese ovulatory subjects (control group) were identified by endovaginal ultrasound during the ovulation period and the presence of at least one follicle greater than 16 mm in diameter.
PCOS is diagnosed after the exclusion of other endocrinopathies (e.g. hypo/hyperthyroidism, hyperprolactemia, Cushing syndrome, etc.) if any 2 out of the 3 criteria are met: oligoovulation and/or anovulation, clinical and/ or biochemical signs of hyperandrogenism or polycystic ovaries at endovaginal sonography. Women with bilateral fallopian tube obstruction, ovarian and uterine diseases and whose husbands proved to be infertile based on semen analysis according to WHO criteria were excluded. All patients underwent the classic investigation protocol for an infertile couple.
Serum levels of LH, FSH and LH/FSH ratio were measured on day 2 or 3 of the menstrual cycle. The ovarian features characteristic to PCOS (enlarged ovaries with an increased stromal echogenicity and more than 12 subcapsular follicles 2-9 mm in diameter per ovary) were assessed by endovaginal sonography.
Obese women with PCOS (study group) received for ovulation induction clomiphene citrate (50 mg, twice a day) for 5 days starting from day 5 of their menstrual cycle and were subdivided into responsive and unresponsive. The following CC drugs were used: Clomid ® (Global Napi Pharmaceuticals, under license of Hoechst, Marion RousselFrance), Clostilbegyt ® (Egis -Hungary), Serophene ® (Serono -Switzerland), Ova-Mit ® (Remedica -Great Britain). Follicular growth and ovulation detection were monitored by transvaginal ultrasound carried out on day 10 and then every 2-3 days depending on follicular growth until at least 1 follicle over 16 mm and maximum 20 mm in diameter was detected, at which moment hCG was administered (1 ampoule of Pregnyl, NV Organon International, Netherlands, 5000 UI administered i.m.) to trigger ovulation. On the day of hCG ovuation induction endometrial thickness was also assessed by endovaginal ultrasound. If 4 or more over 16 mm follicles were present, hCG was no longer administered due to the increased risk of multiple pregnancy and ovarian hyperstimulation syndrome.
Statistical analysis
It was performed using IBM ® SPSS ® software 19.0. The differences between normaly distributed parameters (independent variables) were tested using ANOVA. Otherwise, nonparametric Kruskal-Wallis test was used, based on the analysis of "assigned" ranks. In order to assess the prediction value of AMH for ovulation induction ROC curve analysis (sensitivity and specificity for the determined cut-off level), logistic regression and Pearson correlation were performed.
RESULTS
Fifty-six obese women with PCOS (study group) were compared with 30 obese normo-ovulatory women (control group). The mean age of the study group was 27.8±3.49, comparable, without significant differences to that of the controls (p=0.26).
LH level was significantly higher (p<0.01) in the obese PCOS patients compared to the fertile obese patients (9.67±2.14 vs. 4.23±1.27 mUI/mL). There were no significant differences between the two groups with regard to FSH levels, the average FSH level in obese PCOS patients being 4.77±1.19 mUI/mL. Higher AMH levels were recorded in the PCOS patients compared to controls, with an average of 3.53±1.3 ng/mL in the study group, compared to 1.91±0.4 ng/mL in the control group (p<0.01)( 
Response to CC treatment for ovulation induction
After ovulation induction with CC, obese women with PCOS (study group) were further subdivided into two groups (responders and non-responders), based on transvaginal ultrasound findings (1 or more follicles >16mm) and progesterone level determined on day 21 of the menstrual cycle after ovulation induction with CC. However, if > 4 folicles larger than 16mm were present hCG was no longer administered. (Table  2) .
Between responders and nonresponders there were no significant differences in age, duration of infertility, weight, height, LH and FSH levels. There were, however, significant differences in AMH levels (p<0.01), endometrial thickness (p<0.01) and progesterone level on day 21 of the menstrual cycle (p<0.01)( Table 2 ).
The degree of predicting the response to ovarian stimulation was first assessed by logistic regression. Multivariate analysis allowed to construct a model to define the predictive factors for a positive response to ovarian stimulation. The results of logistic regression proved that for one unit increase of AMH level or endometrial thickness, the chance of positive response to ovarian stimulation treatment increases 3.3 times (odds ratio = 3.3) and 2 times (odds ratio=2), respectively. The same was true for progesterone level, with a 3.1 times increased chance of positive response to ovarian stimulation treatment. These parameters may be considered predictive factors for treatment response ( Table 3 0.819 (p<0.0001, 95%CI: 0.727-0.912), proving that AMH levels had a good discriminatory power for prediction of good response to clomiphene citrate treatment (Fig. 1) . Figure 2a shows the optimal cut-off values determined by pretest probability and the ratio of falsenegative to false-positive findings (cost ratio). The cut-off value is represented as the horizontal line across the two dot histograms for each test (for each AMH level sensitivity and specificity and cutoff value are determined, resulting a paired dot histogram). The best tradeoff was found for an AMH cut-off value of 1.91 ng/mL, which has a sensitivity of 60% and specificity of 95% for predicting the response to clomiphene citrate treatment in obese women with PCOS (Fig. 2b) .
There was no significant correlation between between AMH levels and the number of follicles > 16mm identified by endovaginal ultrasound on the day of hCG administration the correlation coefficient (Pearson r =-0.46, p=0.112). AMH levels also showed a low degree of correlation with antral follicle count (AFC), but significantly correlated with FSH (r=-0.313, p=0.0233) and Table 4 . ROC curve analysis, PCOS group estradiol levels (r=-0.306, p=0.0309) (Fig. 3) . There was no significant correlation between AMH and patient age (r=-0.1154, p=0.290).
DISCUSSION
Measurement of serum AMH is a valuable marker for PCOS patients, used to confirm diagnosis and evaluate the extent of follicular dysfunction in relation with hyperandrogenism and menstrual disturbances (6) . According to the literature the incidence of PCOS in obese women is of 50 percent (7) . In this study, all PCOS women had a BMI > 30 kg/m 2 . Serum AMH level was significantly higher (p<0.001) in obese women with PCOS (3.53±1.3 ng/mL) as compared to obese patients in the control group (1.91±0.4 ng/mL). This finding is in agreement with previous reports in the literature (8, 9) .
Higher serum AMH levels and increased antral follicle count at the beginning of the follicular phase are significantly statistically associated with the number of chemical and clinical pregnancies obtained after controlled ovarian stimulation in vitro fertilization cycles.
Previous studies showed that AMH correlates with the number of retrieved oocytes and is capable to identify the ovarian stimulation response in extreme situations (high-responders or poor-responders), but cannot predict a pregnancy outcome in vitro fertilization cycles (5). In our study, a significant difference in serum AMH level was found between obese PCOS women who responded to clomiphene Figure 2b . Sensitivity-specificity relationship (trade-off) for an AMH cut-off value of 1.91 ng/mL. PCOS group (n=56). citrate treatment (mean AMH level: 5.39±0.76 ng/mL) and the women who did not respond to treatment, the latter presenting significantly lower AMH levels (2.96±0.81 ng/mL). The comparisons between the two groups were made based on the response to ovulation induction, which is a clinically oriented one. It is worth mentioning that FSH concentration did not show significant differences between clomiphene citrate responders and nonresponders (p=0.238).
Considering these results, we may claim that in obese women with PCOS serum AMH level is a more accurate predictor of the response to ovulation induction with clomiphene citrate than FSH. An important advantage of AMH over FSH is the fact that AMH can be measured on any day of the cycle, not only on day 3, but AMH measurement is still expensive, whereas FSH measurement is largely available in all laboratories.
The study pointed out the absence of a correlation between serum AMH level and the number of follicles >16mm (r=-0.46, p=0.112). This owes to the method of ovarian stimulation with clomiphene citrate which allows the development of one or two follicles.
The data have been further analyzed in view of defining the AMH threshold value (cut-off value) for the positive response to ovarian stimulation treatment. Based on the ROC curve used to estimate the sensitivity and specificity of the prediction method, the cut-off level of serum AMH was calculated. In this study, a cut-off value of 1.91ng/mL was found to predict the ovarian response to CC with a sensitivity of 60% and a specificity of 95%. Additional studies are required to define cut-off values for clinical application. The study conducted in 2007 by Samir El-Halawaty reported an AMH cut-off value of 1.21ng/mL (10) .
Previous studies showed a close correlation between obesity and severity of PCOS symptoms and there is growing evidence suggesting that adipose tissue plays a key role in the development and maintenance of the PCOS (7). The results of this study could also provide additional evidence to support the relationship between obesity and PCOS.
In conclusion, AMH levels could be useful in predicting ovarian response to clomiphene citrate treatment in anovulatory obese women, but this needs to be tested in larger, randomized controlled trials.
